Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
4 drugs in development
By Therapeutic Area
top 6
R&D Momentum
83/100
Pipeline Velocity
60/100
Trial Completion Rate
65/100
Pipeline Concentration
9/100
Pipeline Freshness
80/100
Strategic Signals
Activity
Last 14 days
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs and Other Psychoactive Medications in US Nursing Homes Surrounding the COVID-19 Pandemic
Assessing Pediatric Endpoints in DM1 (ASPIRE-DM1)
Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Defining Endpoints in Becker Muscular Dystrophy
Olutasidenib Single Agent as Maintenance Therapy in IDH1mut AML After Induction and Consolidation
Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa
A Randomized Controlled Trial Using a Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer
Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia
Single FrAction Interstitial BreaSt BracHytherApy (SASHA)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)